|
|
|
Advances in newly developing therapy for chronic hepatitis C virus infection |
Paul J. Pockros( ) |
| Division of Gastro/Hepatology, Scripps Clinic, 10666 N Torrey Pines Road, N203, La Jolla, CA 92067, USA |
|
|
|
|
Abstract Chronic hepatitis C virus (HCV) infection afflicts a reported 170 million people worldwide and is often complicated by cirrhosis and hepatocellular carcinoma. Morbidity and mortality are decreased with the successful treatment of chronic HCV infection. Increased understanding of the HCV has allowed further development of new direct-acting antiviral (DAA) agents against the HCV and has also allowed the development of IFN-free oral treatment regimens. In late 2013 the first nucleotide polymerase inhibitor regimen with RBV alone for genotypes 2/3 and in combination with a 12-week regimen of PEG-IFN+RBV for genotypes 1, 4 was approved for use in the US. A number of promising new DAA regimens which are IFN-free are in phase 3 development and the first will likely be approved for use in the US in 2014. The currently approved regimens are discussed in detail and currently available data on future regimens are reviewed herein.
|
| Keywords
direct-acting antiviral (DAA)
nucleotide polymerase inhibitors
protease inhibitors
|
|
Issue Date: 21 May 2014
|
|
| 1 |
F Poordad, D Dieterich. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012; 19(7): 449−464
https://doi.org/10.1111/j.1365-2893.2012.01617.x
pmid: 22676357
|
| 2 |
PJ Pockros. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010; 3(3): 191−202
https://doi.org/10.1177/1756283X10363055
pmid: 21180601
|
| 3 |
US Food and Drug Administration. Approval of Victrelis (boceprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV).
|
| 4 |
US Food and Drug Administration. Approval of Incivek (telaprevir) a direct acting antiviral drug (DAA) to treat hepatitis C virus (HCV).
|
| 5 |
F Poordad, J Jr McCone, BR Bacon, S Bruno, MP Manns, MS Sulkowski, IM Jacobson, KR Reddy, ZD Goodman, N Boparai, MJ DiNubile, V Sniukiene, CA Brass, JK Albrecht, JP Bronowicki; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1195−1206
https://doi.org/10.1056/NEJMoa1010494
pmid: 21449783
|
| 6 |
IM Jacobson, JG McHutchison, G Dusheiko, AM Di Bisceglie, KR Reddy, NH Bzowej, P Marcellin, AJ Muir, P Ferenci, R Flisiak, J George, M Rizzetto, D Shouval, R Sola, RA Terg, EM Yoshida, N Adda, L Bengtsson, AJ Sankoh, TL Kieffer, S George, RS Kauffman, S Zeuzem; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364(25): 2405−2416
https://doi.org/10.1056/NEJMoa1012912
pmid: 21696307
|
| 7 |
JG McHutchison, MP Manns, AJ Muir, NA Terrault, IM Jacobson, NH Afdhal, EJ Heathcote, S Zeuzem, HW Reesink, J Garg, M Bsharat, S George, RS Kauffman, N Adda, AM Di Bisceglie; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010; 362(14): 1292−1303
https://doi.org/10.1056/NEJMoa0908014
pmid: 20375406
|
| 8 |
BR Bacon, SC Gordon, E Lawitz, P Marcellin, JM Vierling, S Zeuzem, F Poordad, ZD Goodman, HL Sings, N Boparai, M Burroughs, CA Brass, JK Albrecht, R Esteban; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364(13): 1207−1217
https://doi.org/10.1056/NEJMoa1009482
pmid: 21449784
|
| 9 |
FDA Drug Safety Communication. Serious skin reactions after combination treatment with the hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin.
|
| 10 |
F Suzuki, H Sezaki, N Akuta, Y Suzuki, Y Seko, Y Kawamura, T Hosaka, M Kobayashi, S Saito, Y Arase, K Ikeda, M Kobayashi, R Mineta, S Watahiki, Y Miyakawa, H Kumada. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol 2012; 54(4): 352−354
https://doi.org/10.1016/j.jcv.2012.04.024
pmid: 22658798
|
| 11 |
A Ali, C Aydin, R Gildemeister, KP Romano, H Cao, A Ozen, D Soumana, A Newton, CJ Petropoulos, W Huang, CA Schiffer. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol 2013; 8(7): 1469−1478
https://doi.org/10.1021/cb400100g
pmid: 23594083
|
| 12 |
D Hunt, P Pockros. What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals? Curr Gastroenterol Rep 2013; 15(1): 303
https://doi.org/10.1007/s11894-012-0303-3
pmid: 23250703
|
| 13 |
Prescribing Information for OLYSIO TM (simeprevir): Janssen Therapeutics, Division of Janssen Products, LP, Titusville NJ 08560. Issued 2013-November
|
| 14 |
MJ Evans, CM Rice, SP Goff. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc Natl Acad Sci USA 2004; 101(35): 13038−13043
https://doi.org/10.1073/pnas.0405152101
pmid: 15326295
|
| 15 |
TL Tellinghuisen, KL Foss, J Treadaway. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4(3): e1000032
https://doi.org/10.1371/journal.ppat.1000032
pmid: 18369478
|
| 16 |
M Gao, RE Nettles, M Belema, LB Snyder, VN Nguyen, RA Fridell, MH Serrano-Wu, DR Langley, JH Sun, DR O’Boyle 2nd, JA Lemm, C Wang, JO Knipe, C Chien, RJ Colonno, DM Grasela, NA Meanwell, LG Hamann. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465(7294): 96−100
https://doi.org/10.1038/nature08960
pmid: 20410884
|
| 17 |
Gilead Sciences Inc. SolvadiTM (sofosbuvir) tablets, for oral use: US prescribing information. 2013.
|
| 18 |
ES Svarovskaia, HS Dvory, C Hebner, et al.. No resistance detected in four phase 3 clinical studies in HCV genotype 1−6 of sofosbuvir+ ribavirin with or without peginterferon. Hepatology 2013; 58(4 Suppl): 1091A−1092A (abstract No. 1843)
|
| 19 |
ES Svarovskaia, H Dvory-Sobol, V Gontcharova, et al.. Comprehensive resistance testing in patients who relapsed after treatment with sofosbuvir (GS-7977)-containing regimens in phase 2 studies. Hepatology 2012; 56(4 Suppl): 551A (abstract No. 753)
|
| 20 |
KV Kowdley, E Lawitz, I Crespo, T Hassanein, MN Davis, M DeMicco, DE Bernstein, N Afdhal, JM Vierling, SC Gordon, JK Anderson, RH Hyland, H Dvory-Sobol, D An, RG Hindes, E Albanis, WT Symonds, MM Berrey, DR Nelson, IM Jacobson. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381(9883): 2100−2107
https://doi.org/10.1016/S0140-6736(13)60247-0
pmid: 23499440
|
| 21 |
E Lawitz, JP Lalezari, T Hassanein, KV Kowdley, FF Poordad, AM Sheikh, NH Afdhal, DE Bernstein, E Dejesus, B Freilich, DR Nelson, DT Dieterich, IM Jacobson, D Jensen, GA Abrams, JM Darling, M Rodriguez-Torres, KR Reddy, MS Sulkowski, NH Bzowej, RH Hyland, H Mo, M Lin, M Mader, R Hindes, E Albanis, WT Symonds, MM Berrey, A Muir. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13(5): 401−408
https://doi.org/10.1016/S1473-3099(13)70033-1
pmid: 23499158
|
| 22 |
EJ Gane, CA Stedman, RH Hyland, X Ding, E Svarovskaia, WT Symonds, RG Hindes, MM Berrey. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368(1): 34−44
https://doi.org/10.1056/NEJMoa1208953
pmid: 23281974
|
| 23 |
E Lawitz, A Mangia, D Wyles, M Rodriguez-Torres, T Hassanein, SC Gordon, M Schultz, MN Davis, Z Kayali, KR Reddy, IM Jacobson, KV Kowdley, L Nyberg, GM Subramanian, RH Hyland, S Arterburn, D Jiang, J McNally, D Brainard, WT Symonds, JG McHutchison, AM Sheikh, Z Younossi, EJ Gane. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368(20): 1878−1887
https://doi.org/10.1056/NEJMoa1214853
pmid: 23607594
|
| 24 |
IM Jacobson, SC Gordon, KV Kowdley, EM Yoshida, M Rodriguez-Torres, MS Sulkowski, ML Shiffman, E Lawitz, G Everson, M Bennett, E Schiff, MT Al-Assi, GM Subramanian, D An, M Lin, J McNally, D Brainard, WT Symonds, JG McHutchison, K Patel, J Feld, S Pianko, DR Nelson; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368(20): 1867−1877
https://doi.org/10.1056/NEJMoa1214854
pmid: 23607593
|
| 25 |
S Zeuzem, GM Dusheiko, R Salupere, et al.. Sofosbuvir+ ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013; 58(4 Suppl): 733A−734A (abstract No. 1085)
|
| 26 |
MS Sulkowski, M Rodriguez-Torres, JP Lalezari, et al.. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Hepatology 2013; 58(4 Suppl): 313A−314A (abstract No. 212)
|
| 27 |
MP Curry, X Forns, RT Chung, et al.. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013; 58(4 Suppl): 314A−315A (abstract No. 213)
|
| 28 |
MR Charlton, EJ Gane, MP Manns, et al.. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Hepatology 2013; 58(6 Suppl): 1378A (abstract No. LB-2)
|
| 29 |
R Flisiak, A Horban, P Gallay, M Bobardt, S Selvarajah, A Wiercinska-Drapalo, E Siwak, I Cielniak, J Higersberger, J Kierkus, C Aeschlimann, P Grosgurin, V Nicolas-Métral, JM Dumont, H Porchet, R Crabbé, P Scalfaro. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008; 47(3): 817−826
https://doi.org/10.1002/hep.22131
pmid: 18302285
|
| 30 |
R Flisiak, SV Feinman, M Jablkowski, A Horban, W Kryczka, M Pawlowska, JE Heathcote, G Mazzella, C Vandelli, V Nicolas-Métral, P Grosgurin, JS Liz, P Scalfaro, H Porchet, R Crabbé. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009; 49(5): 1460−1468
https://doi.org/10.1002/hep.22835
pmid: 19353740
|
| 31 |
JM Pawlotsky, SK Sarin, G Foster, et al.. Alisporivir plus ribavirin is highly effective as interferon-free or interferon add- on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study[abstract No. LB 11]. 47th Annual 791 Meeting of the European Association for the Study of the Liver; 2012-Apr; Barcelona
|
| 32 |
J Au, PJ Pockros. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014; 95(1): 78−88
https://doi.org/10.1038/clpt.2013.206
pmid: 24126682
|
| 33 |
E Lawitz, FF Poordad, PS Pang, RH Hyland, X Ding, H Mo, WT Symonds, JG McHutchison, FE Membreno. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383(9916): 515−523
https://doi.org/10.1016/S0140-6736(13)62121-2
pmid: 24209977
|
| 34 |
EJ Gane, CA Stedman, RH Hyland, et al.. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin: data from the ELECTRON trial. 64th Annual Meeting of the American Association for the Study of Liver diseases, 2013-November-1−5, Washington, USA; abstract 73
|
| 35 |
F Poordad, E Lawitz, KV Kowdley, DE Cohen, T Podsadecki, S Siggelkow, M Heckaman, L Larsen, R Menon, G Koev, R Tripathi, T Pilot-Matias, B Bernstein. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368(1): 45−53
https://doi.org/10.1056/NEJMoa1208809
pmid: 23281975
|
| 36 |
KV Kowdley, E Lawitz, F Poordad, DE Cohen, DR Nelson, S Zeuzem, GT Everson, P Kwo, GR Foster, MS Sulkowski, W Xie, T Pilot-Matias, G Liossis, L Larsen, A Khatri, T Podsadecki, B Bernstein. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014; 370(3): 222−232
https://doi.org/10.1056/NEJMoa1306227
pmid: 24428468
|
| 37 |
DE Cohen, W Xie, L Larsen, et al.. Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects with Ribavirin Dose Reductions 64th Annual Meeting of the American Association for the Study of Liver diseases, 2013-November-1−5, Washington, USA; abstract 1118
|
| 38 |
GT Everson, KD Sims, PJ Thuluvath, et al.. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naïve patients with chronic HCV genotype 1 infection. 64th Annual Meeting of the American Association for the Study of Liver diseases, 2013-November-1−5, Washington, USA; abstract LB1
|
| 39 |
AS Lok, DF Gardiner, E Lawitz, C Martorell, GT Everson, R Ghalib, R Reindollar, V Rustgi, F McPhee, M Wind-Rotolo, A Persson, K Zhu, DI Dimitrova, T Eley, T Guo, DM Grasela, C Pasquinelli. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366(3): 216−224
https://doi.org/10.1056/NEJMoa1104430
pmid: 22256805
|
| 40 |
MS Sulkowski, DF Gardiner, M Rodriguez-Torres, KR Reddy, T Hassanein, I Jacobson, E Lawitz, AS Lok, F Hinestrosa, PJ Thuluvath, H Schwartz, DR Nelson, GT Everson, T Eley, M Wind-Rotolo, SP Huang, M Gao, D Hernandez, F McPhee, D Sherman, R Hindes, W Symonds, C Pasquinelli, DM Grasela; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370(3): 211−221
https://doi.org/10.1056/NEJMoa1306218
pmid: 24428467
|
| 41 |
IM Jacobson, T Asselah, P Ferenci, et al.. STARTVerso3: A randomized, double-blind, placebo-controlled Phase III trial of faldaprevir in combination with pegylated interferon alfa-2a and ribavirin in treatment-experienced patients with chronic hepatitis C genotype-1 infection. 64th Annual Meeting of the American Association for the Study of Liver diseases, 2013-November-1−5, Washington, USA; abstract 1100
|
| 42 |
S Zeuzem, V Soriano, T Asselah, JP Bronowicki, AW Lohse, B Müllhaupt, M Schuchmann, M Bourlière, M Buti, SK Roberts, EJ Gane, JO Stern, R Vinisko, G Kukolj, JP Gallivan, WO Böcher, FJ Mensa. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369(7): 630−639
https://doi.org/10.1056/NEJMoa1213557
pmid: 23944300
|
| 43 |
Study of Liver diseases, 2013-November-1−5, Washington, USA; abstract LB20
|
| 44 |
E Lawitz, JM Vierling, A Murillo, et al.. High efficacy and safety of the all-oral combination regimen, MK-5172/MK-8742+/ RBV for 12 weeks in HCV genotype 1 infected patients: the C-WORTHY Study. 64th Annual Meeting of the American Association for the Study of Liver diseases, November-1−5, 2013, Washington; abstract 76
|
| 45 |
IM Jacobson, RH Ghalib, M Rodriguez-Torres, et al.. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study. 64th Annual Meeting of the American Association for the Study of Liver diseases, 2013-November-1−5, Washington, USA; abstract LB3
|
| 46 |
ZM Younossi, ME Singer, HM Mir, L Henry, S Hunt. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60(3): 530−537
https://doi.org/10.1016/S0168-8278(13)60514-0
pmid: 24269472
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
